Social Europe

politics, economy and employment & labour

  • Themes
    • European digital sphere
    • Recovery and resilience
  • Publications
    • Books
    • Dossiers
    • Occasional Papers
    • Research Essays
    • Brexit Paper Series
  • Podcast
  • Videos
  • Newsletter

How to develop a Covid-19 vaccine for all

Mariana Mazzucato and Els Torreele 29th April 2020

Ensuring no one is left behind requires not just unprecedented collective investment but a very different approach to innovation.

Covid-19 vaccine
Mariana Mazzucato

In the early weeks of 2020, it started to dawn on people that Covid-19 could be the long-dreaded but expected ‘Disease X’—a global pandemic caused by an unknown virus. Three months later, the majority of the world’s population is in lockdown, and it is clear that we are only as healthy as our neighbours—locally, nationally and internationally.

Strong health systems, adequate testing capacity and an effective, universally available vaccine will be key to protecting societies from Covid-19. But ensuring that no one is left behind requires not just unprecedented collective investment, but also a very different approach.

Covid-19 vaccine
Els Torreele

Researchers at universities and companies around the world are racing to develop a vaccine. And current progress is encouraging: 73 vaccine candidates are actively being explored or are in preclinical development, while five already have entered clinical trials.

Public investment

These massive efforts are possible only because of substantial public investment, including by the US National Institutes of Health and the Coalition for Epidemic Preparedness Innovations (CEPI). The latter, a publicly funded non-profit organisation, was established after the 2014-16 west-African Ebola epidemic to drive research and development of vaccines that could be deployed during disease outbreaks.

Our job is keeping you informed!


Subscribe to our free newsletter and stay up to date with the latest Social Europe content.


We will never send you spam and you can unsubscribe anytime.

Thank you!

Please check your inbox and click on the link in the confirmation email to complete your newsletter subscription.

.

CEPI has so far received an extra $765 million of a targeted $2 billion in funding for Covid-19 vaccine development from multiple governments. The Biomedical Advanced Research and Development Authority, part of the US Department of Health and Human Services, has invested substantially in vaccine-development projects with Johnson & Johnson ($450 million) and Moderna ($483 million). And the European Union intends to mobilise further public funding to tackle the pandemic at an online pledging conference on May 4th.

But investment alone is not enough. To succeed, the entire vaccine-innovation process, from research and development to access, must be governed by clear and transparent rules of engagement based on public-interest goals and metrics. That, in turn, will require a clear alignment between global and national public interests.

Mission-oriented approach

The first, critical step is to adopt a mission-oriented approach that focuses both public and private investments on achieving a clearly defined common goal: developing an effective Covid-19 vaccine(s) that can be produced at global scale rapidly and made universally available for free. Realizing this aim will require firm rules regarding intellectual property (IP), pricing and manufacturing, designed and enforced in ways that value international collaboration and solidarity, rather than competition between countries.

Secondly, to maximise the impact on public health, the innovation ecosystem must be steered to use collective intelligence to accelerate advances. Science and medical innovation thrives and progresses when researchers exchange and share knowledge openly, enabling them to build upon one another’s successes and failures in real time.

But today’s proprietary science does not follow that model. Instead, it promotes secretive competition, prioritises regulatory approval in wealthy countries over wide availability and global public-health impact, and erects barriers to technological diffusion. And, although voluntary intellectual-property pools like the one that Costa Rica has proposed to the World Health Organization can be helpful, they risk being ineffective as long as private, for-profit companies are allowed to retain control over critical technologies and data—even when these were generated with public investments.


We need your support


Social Europe is an independent publisher and we believe in freely available content. For this model to be sustainable, however, we depend on the solidarity of our readers. Become a Social Europe member for less than 5 Euro per month and help us produce more articles, podcasts and videos. Thank you very much for your support!

Become a Social Europe Member

Moreover, collective steering is vital to select and pursue the most promising potential vaccines. Otherwise, marketing authorisation may go to the best-resourced candidate rather than the most suitable one.

Capacity and infrastructure

Thirdly, countries must take the lead in building and buttressing manufacturing capabilities, particularly in the developing world. While an effective Covid-19 vaccine probably will not be available for another 12-18 months, a concerted effort is needed now to put in place the public and private capacity and infrastructure needed to produce rapidly the billions of doses that will be required.

Because we don’t know yet which vaccine will prove most effective, we may need to invest in a range of assets and technologies. This poses a technological and financial risk that can be overcome only with the help of entrepreneurial states backed by collective, public-interest-driven financing, such as from national and regional development banks, the World Bank and philanthropic foundations.

Finally, conditions for ensuring global, equitable and affordable access must be built into any vaccine-development programme from the start. This would allow public investments to be structured less like a handout or simple market-fixer, and more like a proactive market-shaper, driven by public objectives.

Pricing of Covid-19 vaccines should reflect both the substantial public contribution to their development and the urgency and magnitude of the global health crisis. We must go beyond statements of principle and generic pledges, and introduce concrete conditions that enable vaccines to be free at the point of use. Policy-makers should also consider using compulsory licensing to allow countries to make the best use of the available tools and technologies.

Crucially, we need collective procurement mechanisms that ensure fair allocation and equitable global access to the new vaccines as they become available. The overriding goal must be to prevent advanced economies from monopolising the global supply or crowding out demand from poorer countries.

Public interest

The Covid-19 crisis rules out a business-as-usual approach. As countries mobilise collectively against the pandemic through calls for a global alliance, pledging conferences, G20 meetings and the upcoming annual World Health Assembly, we cannot afford to miss this chance. These collective efforts must include clear and enforceable rules of engagement that commit all partners to an end-to-end approach to health innovation based on the public interest—an effective Covid-19 vaccine that can be rapidly made available to all for free.

Developing an effective and universally available Covid-19 vaccine is one of the most critical missions of our lifetime. Above all, it is a litmus test of whether global public-private co-operation, touted by policy-makers as the key to success, will maximise the supply of public goods or the share of private profits.

Republication forbidden—copyright Project Syndicate 2020, ‘How to develop a Covid-19 vaccine for all’

Mariana Mazzucato and Els Torreele

Mariana Mazzucato is professor of the economics of innovation and public value and director of the University College London Institute for Innovation and Public Purpose (IIPP); she is author of The Value of Everything: Making and Taking in the Global Economy (Allen Lane, 2019). Els Torreele is executive director of the Médecins Sans Frontières Access Campaign.

Home ・ Politics ・ How to develop a Covid-19 vaccine for all

Most Popular Posts

schools,Sweden,Swedish,voucher,choice Sweden’s schools: Milton Friedman’s wet dreamLisa Pelling
world order,Russia,China,Europe,United States,US The coming world orderMarc Saxer
south working,remote work ‘South working’: the future of remote workAntonio Aloisi and Luisa Corazza
Russia,Putin,assets,oligarchs Seizing the assets of Russian oligarchsBranko Milanovic
Russians,support,war,Ukraine Why do Russians support the war against Ukraine?Svetlana Erpyleva

Most Recent Posts

Gazprom,Putin,Nordstream,Putin,Schröder How the public loses out when politicians cash inKatharina Pistor
defence,europe,spending Ukraine and Europe’s defence spendingValerio Alfonso Bruno and Adriano Cozzolino
North Atlantic Treaty Organization,NATO,Ukraine The Ukraine war and NATO’s renewed credibilityPaul Rogers
transnational list,European constituency,European elections,European public sphere A European constituency for a European public sphereDomènec Ruiz Devesa
hydrogen,gas,LNG,REPowerEU EU hydrogen targets—a neo-colonial resource grabPascoe Sabido and Chloé Mikolajczak

Other Social Europe Publications

The transatlantic relationship
Women and the coronavirus crisis
RE No. 12: Why No Economic Democracy in Sweden?
US election 2020
Corporate taxation in a globalised era

ETUI advertisement

Bilan social / Social policy in the EU: state of play 2021 and perspectives

The new edition of the Bilan social 2021, co-produced by the European Social Observatory (OSE) and the European Trade Union Institute (ETUI), reveals that while EU social policy-making took a blow in 2020, 2021 was guided by the re-emerging social aspirations of the European Commission and the launch of several important initiatives. Against the background of Covid-19, climate change and the debate on the future of Europe, the French presidency of the Council of the EU and the von der Leyen commission must now be closely scrutinised by EU citizens and social stakeholders.


AVAILABLE HERE

Eurofound advertisement

Living and working in Europe 2021

The Covid-19 pandemic continued to be a defining force in 2021, and Eurofound continued its work of examining and recording the many and diverse impacts across the EU. Living and working in Europe 2021 provides a snapshot of the changes to employment, work and living conditions in Europe. It also summarises the agency’s findings on issues such as gender equality in employment, wealth inequality and labour shortages. These will have a significant bearing on recovery from the pandemic, resilience in the face of the war in Ukraine and a successful transition to a green and digital future.


AVAILABLE HERE

Foundation for European Progressive Studies Advertisement

EU Care Atlas: a new interactive data map showing how care deficits affect the gender earnings gap in the EU

Browse through the EU Care Atlas, a new interactive data map to help uncover what the statistics are often hiding: how care deficits directly feed into the gender earnings gap.

While attention is often focused on the gender pay gap (13%), the EU Care Atlas brings to light the more worrisome and complex picture of women’s economic inequalities. The pay gap is just one of three main elements that explain the overall earnings gap, which is estimated at 36.7%. The EU Care Atlas illustrates the urgent need to look beyond the pay gap and understand the interplay between the overall earnings gap and care imbalances.


BROWSE THROUGH THE MAP

Hans Böckler Stiftung Advertisement

Towards a new Minimum Wage Policy in Germany and Europe: WSI minimum wage report 2022

The past year has seen a much higher political profile for the issue of minimum wages, not only in Germany, which has seen fresh initiatives to tackle low pay, but also in those many other countries in Europe that have embarked on substantial and sustained increases in statutory minimum wages. One key benchmark in determining what should count as an adequate minimum wage is the threshold of 60 per cent of the median wage, a ratio that has also played a role in the European Commission's proposals for an EU-level policy on minimum wages. This year's WSI Minimum Wage Report highlights the feasibility of achieving minimum wages that meet this criterion, given the political will. And with an increase to 12 euro per hour planned for autumn 2022, Germany might now find itself promoted from laggard to minimum-wage trailblazer.


FREE DOWNLOAD

About Social Europe

Our Mission

Article Submission

Membership

Advertisements

Legal Disclosure

Privacy Policy

Copyright

Social Europe ISSN 2628-7641

Social Europe Archives

Search Social Europe

Themes Archive

Politics Archive

Economy Archive

Society Archive

Ecology Archive

Follow us on social media

Follow us on Facebook

Follow us on Twitter

Follow us on LinkedIn

Follow us on YouTube